

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7364210

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Execution Date
NEURELIS, INC.	06/01/2022
AEGIS THERAPEUTICS, LLC	06/01/2022

**RECEIVING PARTY DATA**

<b>Name:</b>	ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
<b>Street Address:</b>	601 LEXINGTON AVENUE, 54TH FLOOR
<b>Internal Address:</b>	C/O ORBIMED ADVISORS LLC
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10022

**PROPERTY NUMBERS Total: 18**

Property Type	Number
Application Number:	17396044
Application Number:	63280331
Application Number:	63276760
Application Number:	17570535
Application Number:	63276761
Application Number:	63280333
Application Number:	63280334
Application Number:	63323592
Application Number:	17381500
Application Number:	63284033
Application Number:	63289435
Application Number:	63289437
Application Number:	63289485
Application Number:	17319221
Application Number:	17824419
Application Number:	17721595
Application Number:	63229300
Application Number:	63280332

PATENT

**CORRESPONDENCE DATA****Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Email:** akwon@cov.com**Correspondent Name:** COVINGTON & BURLING LLP**Address Line 1:** ONE CITY CENTER, 850 TENTH ST NW**Address Line 2:** ATTN: PATENT DOCKET**Address Line 4:** WASHINGTON, D.C. 20001**ATTORNEY DOCKET NUMBER:** 034550.00075**NAME OF SUBMITTER:** ASHLEY M. KWON**SIGNATURE:** /Ashley M. Kwon/**DATE SIGNED:** 06/03/2022**Total Attachments: 6**

source=Neurelis - Patent Security Agreement Supplement [Execution Version]#page1.tif

source=Neurelis - Patent Security Agreement Supplement [Execution Version]#page2.tif

source=Neurelis - Patent Security Agreement Supplement [Execution Version]#page3.tif

source=Neurelis - Patent Security Agreement Supplement [Execution Version]#page4.tif

source=Neurelis - Patent Security Agreement Supplement [Execution Version]#page5.tif

source=Neurelis - Patent Security Agreement Supplement [Execution Version]#page6.tif

PATENT SECURITY AGREEMENT SUPPLEMENT

This PATENT SECURITY AGREEMENT SUPPLEMENT, dated as of June 1, 2022 (this "Agreement"), is made by Neurelis, Inc., a Delaware corporation (the "Borrower"), and Aegis Therapeutics, LLC, a California limited liability company (together with the Borrower, each a "Grantor" and collectively, the "Grantors"), in favor of ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP, a Delaware limited partnership (together with its Affiliates, successors, transferees and assignees, the "Lender").

W I T N E S S E T H :

WHEREAS, pursuant to the Credit Agreement, dated as of August 5, 2021 (as amended, supplemented or otherwise modified from time to time, the "Credit Agreement"), by and between the Borrower and the Lender, the Lender has extended Commitments to make Loans to the Borrower;

WHEREAS, in connection with the Credit Agreement, the Grantors and their Affiliates have executed and delivered a Pledge and Security Agreement in favor of the Lender, dated as of August 5, 2021 (as amended, supplemented or otherwise modified from time to time, the "Security Agreement");

WHEREAS, pursuant to the Credit Agreement and pursuant to clause (f) of Section 4.5 of the Security Agreement, each Grantor is required to execute and deliver this Agreement and to grant to the Lender a continuing security interest in all of the Patent Collateral (as defined below) to secure all of the Obligations; and

WHEREAS, each Grantor has duly authorized the execution, delivery and performance of this Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees, for the benefit of the Lender, as follows:

SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.

SECTION 2. Grant of Security Interest. Each Grantor hereby grants to the Lender, for its benefit, a continuing security interest in all of such Grantor's right, title and interest in and to the Patent Collateral, including each patent and patent application referred to in Item A of Schedule I attached hereto and each patent license referred to in Item B of Schedule I attached hereto.

SECTION 3. Security Agreement. This Agreement has been executed and delivered by each Grantor for the purpose of registering the security interest of the Lender in the Patent Collateral with the United States Patent and Trademark Office. The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Lender for its benefit under the Security Agreement. The Security Agreement (and all rights

and remedies of the Lender thereunder) shall remain in full force and effect in accordance with its terms.

SECTION 4. Release of Liens. Upon (a) the Disposition of Patent Collateral in accordance with the Credit Agreement or (b) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (i) such Patent Collateral (in the case of clause (a)) or (ii) all Patent Collateral (in the case of clause (b)). Upon any such Disposition or termination, the Lender will, at such Grantor's sole expense, deliver to such Grantor, without any representations, warranties or recourse of any kind whatsoever, all Patent Collateral held by the Lender hereunder, and execute and deliver to such Grantor such documents as such Grantor shall reasonably request to evidence such termination.

SECTION 5. Acknowledgment. Each Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.

SECTION 6. Loan Document. This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof.

SECTION 7. Governing Law. THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Agreement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements, written or oral, with respect thereto.

SECTION 8. Effectiveness. This Agreement shall become effective when a counterpart hereof executed by the Grantors, shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g., "pdf" or "tiff") or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

*[Signature Page Follows.]*

IN WITNESS WHEREOF, each Grantor hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

NEURELIS, INC.

By: 

Name: Craig Chambliss  
Title: President and Chief Executive Officer

AEGIS THERAPEUTICS, LLC

By: Neurelis, Inc., its sole member

By: 

Name: CRAIG CHAMBLISS  
Title: CEO

*[Signature Page to Patent Security Agreement Supplement]*

**PATENT**  
**REEL: 060096 FRAME: 0043**

SCHEDULE I  
to Patent Security Agreement Supplement

Item A. Patents.

Case Number	Sub Case	Country	Application No.	Filing Date	Patent No.	Issue Date	Expiration / Expected Expiration Date (if pending)	Title	Owner Name	Status
148570.034	51-S	United States of America	16/869461	07-May-2020	11191838	07-Dec-2021	06-Feb-2038	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	Aegis Therapeutics, LLC	Granted
148570.034	71-S	United States of America	17/396044	06-Aug-2021			06-Feb-2038	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	Aegis Therapeutics, LLC	Pending
148570.034	81	United States of America	17/824419	25-05-2022			06-Feb-2038	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE	Aegis Therapeutics, LLC	Pending
148570.036	10	United States of America	63/280331	19-Nov-2021			19-Nov-2022	NON-AQUEOUS INTRANASAL DRUG COMPOSITIONS AND METHODS OF THEIR USE	Aegis Therapeutics, LLC	Pending
148570.037	10	United States of America	63/276760	08-Nov-2021			08-Nov-2022	METHODS AND COMPOSITIONS FOR RAPID DELIVERY OF ANTI-SEIZURE THERAPEUTICS	Neurelis, Inc.	Pending
148570.037	01	United States of America	17/570535	07-Jan-2022			07-Jan-2042	METHODS AND COMPOSITIONS FOR RAPID DELIVERY OF ANTI-SEIZURE THERAPEUTICS	Neurelis, Inc.	Pending
148570.038	00	United States of America	63/276761	08-Nov-2021			08-Nov-2022	COMPOSITIONS AND METHODS FOR SINGLE DOSE ANTI-SEIZURE THERAPEUTICS	Neurelis, Inc.	Pending
148570.039	10	United States of America	63/280332	19-Nov-2021			19-Nov-2022	PARENTERAL DRUG COMPOSITIONS AND METHODS OF THEIR USE	Aegis Therapeutics, LLC	Pending
148570.040	10	United States of America	63/280333	19-Nov-2021			19-Nov-2022	NON-AQUEOUS TOPICAL DRUG COMPOSITIONS AND METHODS OF USE	Aegis Therapeutics, LLC	Pending

148570.041	10	United States of America	63/280334	19-Nov-2021			19-Nov-2022	NON-AQUEOUS ORAL DRUG COMPOSITIONS AND METHODS OF USE	Aegis Therapeutics, LLC	Pending
148570.043	81OB	United States of America	17/721,595	15-Apr-2022			13-Jun-2032	ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS	Neurelis, Inc.	Pending
148570.044	10	United States of America	63/323,592	25-Mar-2022			25-Mar-2023	INTRANASAL OLANZAPINE FORMULATIONS AND METHODS OF THEIR USE	Neurelis, Inc.	Pending
148570.049	21	United States of America	16/735359	06-Jan-2020	10857157	08-Dec-2022	09-May-2037	RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF	BioAxone Biosciences, Inc.	Granted
148570.049	31	United States of America	17/381500	21-Jul-2021			09-May-2037	RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF	BioAxone Biosciences, Inc.	Pending
148570.054	00	United States of America	63/284033	30-Nov-2021			30-Nov-2022	METHODS AND COMPOSITIONS FOR INCREASING INTERSEIZURE CLUSTER INTERVAL DURATION	Neurelis, Inc.	Pending
148570.055	00	United States of America	63/289435	14-Dec-2021			14-Dec-2022	TREATMENT OF CAVERNOUS ANGIOMAS WITH A 4-SUBSTITUTED PIPERIDINE DERIVATIVE	Neurelis, Inc.	Pending
148570.056	00	United States of America	63/289437	14-Dec-2021			14-Dec-2022	ACUTE TREATMENT OF CAVERNOUS ANGIOMAS WITH A 4-SUBSTITUTED PIPERIDINE DERIVATIVE	Neurelis, Inc.	Pending
148570.056	10	United States of America	63/289485	14-Dec-2021			14-Dec-2022	ACUTE TREATMENT OF CAVERNOUS ANGIOMAS WITH A 4-SUBSTITUTED PIPERIDINE DERIVATIVE	Neurelis, Inc.	Pending
148570.0057	11-S	United States of America	17/319,221	13-May-2021			11-Jul-2039	METHODS, PARENTERAL PHARMACEUTICAL FORMULATIONS, AND DEVICES FOR THE PREVENTION OF OPIOID OVERDOSE	Opiant Pharmaceuticals, Inc.	Pending

148570.0058	00-S	United States of America	63/229300	04-Aug-2021		04-Aug-2022	COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSE	Opiant Pharmaceuticals, Inc.	Pending
-------------	------	--------------------------	-----------	-------------	--	-------------	---	------------------------------	---------

Item B. Patent Licenses.

None.